Tunahan Ayaz

Tunahan Ayaz

Auto-generated profile, based on publicly available information

Tunahan Ayaz

Sağlık Bilimleri Üniversitesi, Gülhane Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Ankara

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2020 in Turkish Journal of Parasitology
Verified
Journal Article
Closed access
SISinem Akkaya Işık
Sinem Akkaya Işık
DSDerya Seyman
Derya Seyman
EZEsra Zerdali
Esra Zerdali
SASaliha Ayan
Saliha Ayan
DKDeniz Kakaliçoğlu
Deniz Kakaliçoğlu
ŞKŞükran Köse
Şükran Köse
To determine the clinical characteristics of patients with cystic echinococcosis and the diagnostic and therapeutic approaches used. This is a multicentre, retrospective study. Patients from six centres who were diagnosed with hydatid cysts in the last five years were evaluated. The mean age was 45.4±17.4 years, and 54.7% were female. The most common complaints were abdominal pain, nausea and vomiting, and the most common physical examination finding was abdominal tenderness. Most patients were diagnosed within 2-6 months. Anaemia and eosinophilia were the most common laboratory findings. The liver was the most commonly involved organ (n=153, 90%). One hundred twenty-five (73.5%) patients underwent ultrasonography. The largest cyst was present in the liver at stage four, and its diameter was 160x170 mm. The rates of the negative, grey zone and positive results were 9.4%, 8.8% and 81.8%. Surgery was more common (n=72, 42.4%) than puncture, aspiration, injection, and re-aspiration treatments (n=14, 8.2%). Of the 47 patients who had a recurrence, 22 (46.8%) had a history of hydatid cyst treatment. Hydatid disease, which is endemic in our country, is diagnosed at a late stage. In terms of disease diagnosis, serological tests may be misleading. It was not possible to compare the success rates according to the treatment choices because of the lack of randomisation of stages and sizes of the lesions.

9 June 2021 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
YAYakup Arslan
Yakup Arslan
DDDeniz Dogan
Deniz Dogan
NONesrin Ocal
Nesrin Ocal
AKAlperen Koc
Alperen Koc
TATunahan Ayaz
Tunahan Ayaz
HKHakan Kayir
Hakan Kayir
Objective Coronavirus disease 2019 (COVID-19) is an emerging, fast-spreading, highly mortal and worldwide infectious disease. The pulmonary system was defined as the main target of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the mortality concept of this disease presented with more severe and systemic disease. The present study investigated the relationship between the patient characteristics at the initial hospital administration and fatality in COVID-19 patients. Methods In this retrospective and comparative cohort study, all the 767 hospitalised COVID-19 patients, treated between 18 March and 15 May 2020 in the Covid Clinics of Gulhane Training and Research Hospital in Ankara, Turkey, were evaluated. Results The fatality rate was significantly increased in patients with any comorbid disease except asthma. The initial laboratory test results indicated highly significant differences according to the patient's outcome. A multifactor logistic regression analysis was performed to calculate the adjusted odds ratios for predicting patient outcomes. Being older than 60 years increased the death risk with an adjusted OR of 7.2 (95% CI: 2.23-23.51; P = .001). The presence of a cancer and the extended duration of intensive care unit treatment were other significant risk factors for nonsurvival. Azithromycin treatment was determined as significantly reduced the death ratio in these patients (P = .002). Conclusion It was revealed that being older than 60 years, presence of a cancer and extended duration of ICU treatment were the major risk factors for predicting fatality rate in hospitalised COVID-19 patients.

26 August 2021 in Akademik Gastroenteroloji Dergisi
Verified
Journal Article
Open access
PDF file
HEHarun Erdal
Harun Erdal
ABAyfer Bakır
Ayfer Bakır
ÜSÜmit Savaşçi
Ümit Savaşçi
TATunahan Ayaz
Tunahan Ayaz
HIHilal İşi̇kan
Hilal İşi̇kan
MGMustafa Gülşen
Mustafa Gülşen
Giriş ve Amaç: COVID-19’da karaciğer hasarının ana mekanizmasının, şiddetli akut solunum sendromu koronavirüs-2'nin safra kanalı hücrelerinde yüksek oranda eksprese edilen anjiyotensin dönüştürücü enzim 2 reseptörüne bağlanması olduğu düşünülmektedir. Bu çalışmada COVID-19 tanısı ile yatırılarak takip ve tedavi edilen hastaların, komorbid karaciğer hastalıklarının araştırılması, yatış gününde anormal karaciğer biyokimyasal test sonuçları sıklığının değerlendirilerek hastalığın seyri ve prognozu ile ilişkisinin araştırılması amaçlandı. Gereç ve Yöntem: COVID-19 tanısı ile yatırılarak tedavi edilen 18 yaşından büyük hastalara ait veriler retrospektif olarak değerlendirildi. Hastaların aspartat aminotransferaz, alanin aminotransferaz, alkalen fosfataz, gama glutamil transferaz, total bilirübin değerleri ile hastanede kalış süreleri, yoğun bakım ünitesi ihtiyacı, mortalite arasındaki ilişki araştırıldı. Bulgular: COVID-19 tanısı revers transkripsiyon polimeraz zincir reaksiyonu ile doğrulanmış 795 hastadan 113’ünde (%14.2) yüksek karaciğer enzim (alanin aminotransferaz ve/veya aspartat aminotransferaz) prevalansı saptandı. COVID-19’lu olgularda yüksek alanin aminotransferaz prevalansı %11.1 iken aspartat aminotransferaz prevalansı ise %9.6 idi. Alanin aminotransferaz yüksekliği en fazla 71 yaş ve üstünde (%17.4), aspartat aminotransferaz yüksekliği ise en fazla 51-70 yaş grubunda (%14.8) bulundu. Alanin aminotransferaz ve/veya aspartat aminotransferaz yüksekliği saptanan ve saptanmayan hastalar arasında, hastalığın seyri, hastanede ve yoğun bakımda yatış süresi ve mortalite açısından anlamlı bir fark tespit edilmedi. Ayrıca, aspartat aminotransferaz ve alanin aminotransferaz yüksekliğinin sağ kalım zamanında anlamlı bir fark oluşturmadığı saptandı. Sonuç: COVID-19 hastalarında anormal karaciğer fonksiyon testleri tespit edilebilir. Ancak bunun sebepleri ve prognoza etkileri konusunda yeterli bilgiye sahip olmak için daha geniş popülasyonu içeren prospektif çalışmalara ihtiyaç vardır.

14 July 2022 in Journal of Molecular Virology and Immunology
Verified
Journal Article
Closed access
FCFerhat Cüce
Ferhat Cüce
DDDeniz Doğan
Deniz Doğan
UBUğur Bozlar
Uğur Bozlar
MTMustafa Taşar
Mustafa Taşar
EGErvin Gjoni
Ervin Gjoni
OSOktay Sarı
Oktay Sarı
We investigated whether Chest X-Ray (CXR) could replace computed tomography (CT) modality in the diagnosis and during the treatment of young adult COVID-19 patients with mild dyspnea with no comorbid diseases. This retrospective study involved an examination of the records of a total of 956 patients hospitalized between March 1, 2020, and May 15, 2020. The study included a total of sixty-four COVID-19 patients who underwent a CXR at admission and CT imaging within 24 hours, aged 21-60 years with mild dyspnea with no comorbid diseases. The diagnosis of infection was confirmed by the polymerase chain reaction test in all cases. The first CXR and CT images at the time of admission were evaluated in terms of lesions and localization. The clinical-radiological course of the disease was also statistically evaluated. CT was normal in 18/64 (28.1%) patients, all of whom also had normal CXR. The rest of the patients 46/64 (71.9%) with an abnormal CT, the CXR was normal in 18/46 (39.1%) and abnormal in 28/46 (60.9%). The time between the onset of complaints and admission to the hospital in patients with abnormal and normal CXR was 3.5±2.3 days and 2.1±1.1 days respectively and this difference was statistically significant (p=0.004). The hospital stay durations of the patients with abnormal and normal CXR was 9.6±3.5 and 9.5±3.4 days (p=0.928), respectively, and was not statistically significant. In conclusion, in the case of early admission to the hospital, there is not a significant difference between using CXR or CT in the management of young adult COVID 19 patients with mild dyspnea no comorbid disease. Therefore, the use of CXR in these patient groups will reduce the burden of CT units in pandemic conditions with limited resources.